GlaxoSmithKline (GSK) and The Texas A&M University System announced that the U.S. Department of Health and Human Services (DHHS) approved the establishment of a US$91 million influenza vaccine manufacturing facility as the anchor of the Center for Innovation in Advanced Development and Manufacturing (CIADM) in Bryan-College Station, Texas.  The TAMUS influenza vaccines manufacturing center “will afford GSK the capabilities to eventually manufacture influenza vaccine based on a proprietary cell-culture line, [1]EB66…The cell-culture process will supplement the vaccine supply from eggs, and facilitate a rapid national vaccine response in the event of a pandemic.”

http://www.prnewswire.com/news-releases/texas-am-system-and-glaxosmithkline-receive-us-government-approval-to-establish-influenza-vaccine-facility-in-texas-200046591.html